Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 8/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131308 | 0.98 | ADRB2 (0.45) | ADRB2CHRM3ADRB1DRD2 | |
| SCHEMBL4139870 | 0.90 | ADRB2 (0.57) | ADRB2CHRM3ADRB1 | |
| SCHEMBL4132536 | 0.87 | ADRB2 (0.58) | ADRB2CHRM3ADRB1 | |
| SCHEMBL3958110 | 0.78 | ADRB2 (0.70) | ADRB2ADRB1DRD2 | |
| SCHEMBL4135992 | 0.78 | ADRB2 (0.70) | ADRB2ADRB1DRD2 | |
| SCHEMBL4134389 | 0.77 | ADRB2 (0.59) | ADRB2CHRM3ADRB1 | |
| SCHEMBL4134385 | 0.77 | ADRB2 (0.59) | ADRB2CHRM3ADRB1 | |
| SCHEMBL4143547 | 0.77 | ADRB2 (0.62) | ADRB2ADRB1 | |
| SCHEMBL4143553 | 0.77 | ADRB2 (0.62) | ADRB2ADRB1 | |
| SCHEMBL4135004 | 0.76 | ADRB2 (0.56) | ADRB2CHRM3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | claimed |
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029958-A1 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885CHRM3 13/4885ADRB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.